Lumina Specialist Hospital — Business Model & Revenue Engine
The business model and revenue engine across admissions, theatre and procedure revenue, the payer mix and the unit economics underpinning the hospital.
Section 6 · Business Plan
Business Model & Revenue Engine
The business model and revenue engine across admissions, theatre and procedure revenue, the payer mix and the unit economics underpinning the hospital.
Lumina earns hospital facility revenue — accommodation, theatre,
critical care, consumables and ward medicines — while admitting
specialists bill separately for professional fees. Revenue is built
bottom-up from beds, occupancy and a blended revenue-per-patient-day,
supplemented by chronic and ambulatory programmes.
6.1 Revenue streams
Five streams drive the model. Inpatient and acute care
(accommodation, theatre, ICU and consumables) is the largest, scaling
with commissioned beds and occupancy. Renal dialysis and oncology
provide recurring, programme-based volumes that are less sensitive to
acute occupancy swings. Outpatient and 24/7 emergency, and diagnostic
imaging, complete the mix and feed the inpatient funnel.
| Revenue stream | Driver | Year 1 | Year 4 | Year 7 |
|---|---|---|---|---|
| Inpatient & acute | Beds × occupancy × R/day | R129m | R358m | R463m |
| Renal dialysis | Stations × sessions × fee | R21m | R43m | R55m |
| Oncology | Treatments × fee | R34m | R76m | R106m |
| Outpatient & emergency | Visits × facility fee | R25m | R53m | R73m |
| Diagnostic imaging | Scans × fee | R30m | R63m | R87m |
| Total revenue | R240m | R593m | R784m |
6.2 Payer mix
The patient base is expected to be dominated by medical-scheme
members (the great majority of revenue), supplemented by gap-cover
top-ups, self-funding private patients and a modest cross-border
component. The commercial priority is to secure
designated-service-provider or network status with the major open and
restricted schemes, which converts catchment demand into predictable,
contracted volumes.
| Payer category | Indicative share of revenue | Notes |
|---|---|---|
| Medical schemes (open & restricted) | ~78% | Primary payer; network contracting is critical |
| Gap-cover / co-payment top-ups | ~7% | Supplements scheme tariffs |
| Self-funding private patients | ~11% | Price-sensitive; transparent packages |
| Cross-border & other | ~4% | Eswatini / Mozambique referrals |
6.3 Unit economics & cost shape
At stabilisation, staff costs run at roughly 36–37% of revenue,
medical consumables and pharmacy at about 24.5%, with the remaining
direct and overhead costs taking total operating expenditure to around
80% of revenue — implying a mature EBITDA margin in the low-twenties.
The model treats a large share of staff and overhead as semi-fixed,
which is why early-year margins are compressed during the occupancy ramp
and expand as fixed costs are spread over a larger revenue base.
The model deliberately caps the mature EBITDA margin at about 21%,
below the 22–26% range reported by listed incumbents at scale. This is a
conservative choice appropriate to a single, ramping greenfield without
group procurement leverage; it should be read as a floor that a well-run
platform could exceed, not as an upper bound.
Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of Lumina Health Holdings (Pty) Ltd.